title: Lipid and lipoprotein patterns in type 2 non-obese diabetic patients. Do Lp(a) levels decrease with improved glycemic control in these patients?
abstract: OBJECTIVE
  In this study, we investigated the levels of apolipopotein-AI (apo-AI), apolipoprotein (apo-B), triglyceride (TG), high-density-lipoprotein-cholesterol (HDL-C), low-density-lipoprotein-cholesterol (LDL-C), total cholesterol, lipoprotein(a) in a group of non-obese, type 2 diabetes mellitus patients with different types of treatment and a control group of non-obese, non-diabetic subjects.
  
  
  RESULTS
  Patients were divided into three groups according to their treatment types: insulin, sulphonylurea and untreated groups. All groups were similar in sex, weights, known duration of diabetes and habits. Each group consisted of 30 subjects. There were no differences in apo-AI, apo-B and TG levels (p > 0.05), whereas HDL-C levels in the untreated group were significantly lower than those of the other groups (p < 0.05). Lp(a) levels in the untreated group were higher than in the other (p < 0.05).
  
  
  CONCLUSIONS
  Gaining metabolic control in diabetes mellitus is crucial in pulling back lipid, lipoprotein and apolipoprotein levels to a desired level and in attenuating CAD (coronary artery disease) risk factors, and also in preventing CAD. Lp(a) levels in particular are decreased by insulin or sulfonylurea in non-obese patients with type 2 diabetes mellitus.
authors.affiliation: Department of Internal Medicine, Cumhuriyet University, Sivas, Turkey.
authors.forename: H
authors.initials: H
authors.lastname: Alagözlü
authors.forename: F
authors.initials: F
authors.lastname: Gültekin
authors.forename: F
authors.initials: F
authors.lastname: Candan
mesh_terms: D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*; D017270:Lipoprotein(a) / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D012016:Reference Values; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D001786:Blood Glucose; D002784:Cholesterol; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005907:Gliclazide; D006442:Glycated Hemoglobin; D007328:Insulin; D008055:Lipids; D017270:Lipoprotein(a); D008074:Lipoproteins; D013453:Sulfonylurea Compounds; D014280:Triglycerides